Core Insights - Organon is divesting its JADA post-partum haemorrhage treatment system to Laborie Medical in a deal valued at up to $465 million, with $440 million received at closing and up to $25 million contingent on 2026 revenue targets [1][2] - The transaction is expected to be completed by Q1 2026, with around 100 Organon employees transferring to Laborie as part of the agreement [1] Financial Implications - The sale of JADA is part of Organon's strategy to improve its balance sheet capacity and focus on growth opportunities in women's health biopharma [3] - Organon inherited approximately $9.5 billion in debt when it spun off from MSD in 2021, with current debt reported at $8.9 billion as of Q2 2025 [3] Sales Performance - JADA's sales grew by 40% in 2024, reaching $61 million, but the company is shifting away from medtech women's health devices to concentrate on its biopharma range [4] - Nexplanon, Organon's leading biopharma product, generated around $179 million in revenue in Q2 2025 [4] Corporate Governance Issues - A sales malpractice issue involving Nexplanon led to the resignation of CEO Kevin Ali in October 2025, following a board investigation into improper wholesaler sales practices [5] - Following the malpractice revelations, Organon's stock value dropped by 20.9% from $9.16 to $7.25 within a few days, and the stock has decreased over 60% in the past year, from around $17-$18 in November 2024 to a current price of $6.61 [6]